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Abstract.   Enhancing factor (EF), a mouse phospholipase A2 (PLA2), has been purified from 
the small intestines, based on its ability to increase the binding of epidermal growth factor in 
a radioreceptor assay. EF/PLA2 was found to be localized predominantly in the Paneth cells in 
the small intestines. Whether mouse intestinal EF/PLA2 is identical/similar to mouse secretory  
PLA2 was to be determined. Phospholipases are known to play a crucial role in the process of 
inflammation. This paper reports the presence of trace amounts of EF/PLA2 in the peritoneal 
exudate cells. Western blot analysis of the acid extracts showed the presence of a 14 kDa 
immunologically cross-reactive protein. RT-PCR analysis using EF specific primers amplified  
a ~ 700 bp product which was further confirmed to be EF-specific by nested PCR analysis and  
sequencing. Presence of EF in the peritoneal exudate cells could be a unique mode of transport of  
growth factor modulator to the site of injury to aid in regeneration/cell proliferation of damaged  
tissue. 
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1. Introduction 
 
Enhancing factor (EF) is a 14 kDa heat and acid stable peptide isolated from the mouse
small intestines (Deo et al 1983; Mulherkar and Deo 1986)· Immuno-histochemical
studies have demonstrated that it is predominantly localized in the Paneth cells of small
intestine (Wagle et al 1989; Mulherkar et al 1991; Desai et al 1991) and has been used as
a marker for Paneth cells (Bry et al 1994)· The full length EF cDNA has been obtained 
by RAcE-RT-PCR· Based on the predicted amino acid sequence EF has been shown to
belong to group-II phospholipase A2 (PLA2) (Mulherkar et al 1993a, b)· EF shares
74% similarity with rat platelet PLA2 and 66% similarity with human synovial fluid
PLA2· The PLA2 activity of EF has been confirmed in a blood agar plate assay as well 
as assay with micellar substrate [14C] phosphatidyl choline and deoxycholate (Mul 
herkar et al 1993b)· 
Inflammation is a localized or systemic protective response elicited by injury to cells 
or tissues· Secretory, non-pancreatic phospholipase A2 (sPLA2) has been implicated as 
one of the important pathogenic agents in both local and systemic inflammatory 
conditions (Walsh et al 1983)· Phospholipases are naturally occurring enzymes of lipid 
metabolism which selectively remove the fatty acids and the phosphobase from the 
phospholipid· An extractable Ca2+ dependent PLA2 localized to the granules of
human neutrophils has been reported by Rosenthal et al (1995)· The present study was
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undertaken to investigate if mouse neutrophils synthesize EF/PLA2 and whether it is 
the same as the mouse intestinal EF· Mouse peritoneal exudate cells, a rich source for 
neutrophils, was used for this study· 
 
 
2.Materials and methods   
 
2·1 Animals 
 
Balb/c mice (2-3 months old) used in this study, were obtained from the Animal House, 
Cancer Research Institute, Mumbai· 
 
2·2 Induction of ascites 
 
Starch (2 ml of 2%) was injected i·p· into Balb/c mice and the peritoneal exudate cells
collected at different time points by injecting 5 ml sterile phosphate buffered saline· 
Cells collected from ~ 50 animals were pooled· An aliquot of the cells were used for
Giemsa staining, blood agar plate assay (PLA2 assay) and the remaining for extraction
of acid stable proteins· 
 
2·3 Giemsa staining of exudate cells and blood agar plate assay 
 
The exudate cells were cytospun onto glass slides, fixed in methanol for 10 min, stained 
with Giemsa stain for 15 min and observed under the microscope· Blood agar plates
were made by mixing fresh human red blood cells with agarose prepared in barbitone
buffer pH 7 as described by Habermann and Hardt (1972)· Wells were punched after the
agar was set· Samples (either whole exudate cells, acid extracts or purified fractions) 
were loaded along with appropriate controls (snake venom PLA2 as well as intestinal
EF were used as positive controls and PBS as negative control)· The plates were
observed after incubation at 37°C for 14–16 h· Clear zone around the well indicated
PLA2 activity· 
 
2·4 Acid extraction and fractionation of exudate cell proteins 
 
The protocol for EF extraction as described by Deo et al (1983) was followed to extract
acid soluble proteins from the exudate cells· The acid soluble proteins were purified on 
a Biogel P-100 column as described (Mulherkar et al 1986) and the fractions tested in 
ELISA (as described below)· The positive fractions were pooled and further purified on 
a RP-HPLC column (Waters), as described earlier (Mulherkar et al 1986)· The eluate
was monitored at 280 nm, all the peaks collected separately, lyophilized and tested in 
various assays described below· 
 
2·5 ELISA and Western blot analysis 
 
For ELISA,.200 ng of EF protein in PBS was coated overnight at 4°C in 96 well plates. 
The wells were blocked with 1% skimmed milk in PBS for 2h at 37°C· Primary
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antibody (antiserum raised against EF, described in Wagle et al 1989) was added at 
 a dilution of 1:5000 followed by second antibody (goat anti rabbit antibody tagged to 
horse radish perioxide enzyme) at a dilution of 1:500· Intermittent washes were given
with PBS containing 5% skimmed milk and 1% Tween-20· The final colour was
developed by adding OPD as the substrate prepared in citrate phosphate buffer and the
reaction stopped with 2N H2SO4· The plate was read at 492/690 nm on an ELISA 
reader (Flow Laboratories)· 
For Western blot analysis, proteins were separated on a 17·5% SDS-PAGE gel and 
transferred on to a nitrocellulose membrane in a transblot apparatus (BioRad)· The 
blot was developed using antibodies against EF at a dilution of 1:5000 and ECL kit 
(Amersham) as per the manufacturer's instructions· 
 
2·6 RT-PCR and Southern blot analysis 
 
Total RNA was extracted from the peritoneal exudate cells by the method of Chomcyznski  
and Sacchi (1987) and subjected to first strand cDNA synthesis using oligo(dT) as
 a primer and AMV reverse transcriptase (Amersham)· PCR amplification was carried  
out using Taq DNA polymerase (Amersham) for 30 cycles at 95°C-1', 55°C-2', 72°C-3'
during the last cycle, extension at 72°C was caried out for 10'· Primers used were EFH5'
sense (5' CCCAAGCTTGGGCTGACAGCATGAAGGTCC3') and EFX3' antisense
(5' GCTCTAGAGCCCAGGACTCTCTTAGGTAGG 3')· For nested PCR, primers  
EFH5' sense and EF244-277 antisense (5' TCTGGTTTGCAGAACAGG 3') were 
 used· The expected 315 bp product was obtained· The plasmid pUC-EFcomp carrying 
the full length EF cDNA was used as a control for comparison of the amplified  
products·Theamplified DNA was subjected to Southern blotting using EF cDNA as 
 a probe· 
 
3. Results 
 
Exudate cells collected at 6, 16, 24, 48, 72 and 96 h post starch injection were stained 
 with Giemsa· There was a change in the cell types from the predominant neutrophils in 
the early/acute stages to predominant monocytes in the late/chronic stages of infla-
mmation (data not shown)· Cells collected at 16–18 h showed that more than 90% of 
the cells were neutrophils· These cells were disrupted by sonication and tested in blood 
agar plate assay for PLA2 activity (figure 1)· The exudate cells (figure 1,106 cells in wells 
Nos 2 and 4; and 105 cells in well No· 3) showed PLA2 activity as seen by the clear zones 
around the wells· Snake venom PLA2, a highly purified protein (50 ng), was used as the 
positive control (figure 1, well No· 1) and showed high activity· PBS served as the 
negative control (figure 1, well No· 5)· Partially purified intestinal EF showed a much 
greater activity compared to exudate cells (data not shown)· 
Total acid-soluble proteins, obtained from exudate cells collected from 215  
animals injected with starch, were subjected to fractionation on a Biogel P-100 
column (figure 2)· Alternate fractions were tested in ELISA· Fractions 19–25
showing maximum immunological cross reactivity (figure 2), were pooled, lyophilized, 
reconstituted in distilled water and designated as IEP-P100-A· This pool was further
fractionated on HPLC column· The peak fractions eluting from the column, monitored  
at 280 nm, were lyophilized, run on a SDS-PAGE gel and subjected to Western blot 
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Figure 1·  Blood agar plate assay showing PLA2 activity of exudate cells· 106 cells were 
loaded in well Nos 2 and 4, and 105 cells in well No· 3· Well No· 1 was loaded with 50 ng of 
snake venom PLA2 (Sigma) and well No· 5 with PBS (negative control)·  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Biogel P-100 profile of the acid soluble proteins extracted from exudate cells· Acid 
soluble proteins extracted from exudate cells were separated on Biogel P-100 column  
monitored at 280 nm· The dotted line denotes the fractions showing mmunological cross- 
reactivity in ELISA read at 492 nm· 
 
 
analysis (figure 3)· Lane 1 shows intestinal EF-P100 (17·5 µg, the amount loaded was 
too much in excess), lanes 2, 3, 4 contain fractions of IEP-P100-A pool eluting at 
different time points from the HPLC column, the autoradiogram showed a 14 kDa 
band in the HPLC fraction eluting between 26'-32' (in lane 4) corresponding to the  
Mouse peritoneal exudate cell  533 
 
Figure 3. Western blot analysis of HPLC fractions of exudate cell acid soluble proteins· Proteins 
 were separated on a 17·5% SDS-PAGE and subjected to Western blot analysis· Lane 
 1 shows intestinal EF-P100 (17·5 µg) as a positive control, lanes 2 and 3 contain the HPLC 
protein peak fractions eluting at 21 min (2·3 µg) 25 min (2·3 µg) respectively and lane 4 shows 
 14 kDa band in exudate protein HPLC fraction eluting between 26–32 min (4·2 µg)· 
 
 
control intestinal EF-P100 band in lane 1· The other HPLC fractions in lanes 2 and 3, 
did not show any cross-reactivity. 
Total RNA (5 µg), extracted from exudate cells was subjected to RT-PCR using EF 
specific primers (EFH5' and EFX3') pUC-EFcomp DNA, containing the full length 
cDNA, was used as a positive control· RT-PCR resulted in a ~ 700 bp band which 
corresponded with the positive control (data not shown)· The possibility of non-specific 
amplification was ruled out by doing nested PCR using internal primers EFH5' and 
EF244-227 antisense (figure 4A) and subjecting the same to Southern blot analysis 
(figure 4B)· The gel shows amplification of the expected ~315bp. The amplified 
product was subjected to direct sequencing and was found to be identical to that of 
intestinal EF (data not shown)· 
 
4. Discussion 
 
Secretory phospholipase A2 plays a crucial role in inflammation and in the cascade of 
events following inflammation (Pruzanski and Vadas 1991)· The first biological 
response to injury or inflammation is the massive influx of polymorphonuclear 
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Figure 4. Nested PCR on the 700 bp DNA amplified from exudate cells by RT-PCR using 
EF specific primers, (A) 2% agarose gel stained with ethidium bromide showing a ~ 315 bp 
product (lane 1)· EF cDNA was used as a positive control (lane 2)· (B) Southern blot analysis 
of the same gel using [32P] dCTP labelled EF cDNA as a probe·  
 
leukocytes (PMNL), especially neutrophils, followed by monocytes/macrophages 
during the chronic stages of inflammation· Neutrophil dependent tissue damage in 
inflammation is either because of release of active oxygen species such as O2   and
H2O2, or hydrolytic enzymes, such as proteases and lipases· By the action of PLA2 
rachidonic acid (AA) is released from human neutrophils (Walsh et al 1983)· Balshinde 
et al (1988) have shown release of AA in the surrounding medium after neutrophil 
activation· 
An acid stable, calcium-dependent PLA2 activity has been shown to be present in 
human neutrophil homogenates (Marki and Franson 1986), membrane fractions 
(Frans on et al 1977) and localized to the granules (Rosenthal et al 1995)· Mucosal 
PLA2 was shown to be increased in active colitis· It has been suggested that increased 
intestinal permeability may be a primary factor in activation of mucosal PLA2 in 
intestinal inflammation (Olaison et al 1989)· Thrombin activated platelets and rabbit 
peritoneal neutrophils exposed to fMLP have shown release of PLA2 activity· In case 
of neutrophils, the release of this enzyme coincides with the release of β-glucoronidase 
and lysozyme, thereby suggesting a lysosomal granule origin (Mayer and Marshall 
1993)· 
Here we report the presence of trace amounts of EF protein in the inflammatory 
peritoneal exudate cells of mouse. Acid stable proteins extracted from the exudate cells 
(predominantly neutrophils) showed the presence of a 14 kDa protein, cross-reacting 
immunologically with antibodies to EF· EF has been shown to be localized predomi 
antly in the Paneth cells of small intestine (Wagle et al 1989; Mulherkar et al 1991; 
Desai et al 1991; Bry et al 1994)· Although its precise role in the intestines has not yet 
been established, we have speculated that it plays a role in modulating cell proliferation 
in the intestinal crypts· 
-
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The crude extract was subjected to purification over the Biogel P-100 column and 
RP-HPLC column· The final yield of protein was extremely low· Wright et al (1990) 
have reported a final yield of 6 mg (~ 400 nmol) of the 14 kDa PLA2 starting from 1011 
PMNCs after HPLC purification (constituting just 9% of the total cellular PLA2). 
 In a blood agar plate assay after P-100 as well as HPLC purification the protein 
showed decreased PLA2 activity as compared to the crude protein· The enhancing 
activity was also very low· It has been reported in literature that contamination 
of some sediment of the acid extract, which was lipid extractable, suppresses phos-
pholipase activity (Marki and Franson 1986)· In vitro inhibition of PLA2 activity 
by cis-unsaturated fatty acids has also been shown and thought to be mediated by 
the formation of an enzymatically inactive enzyme-substrate inhibitor complex 
(Raghupathi and Franson 1992)· 
RT-PCR analysis of the total RNA extracted from exudate cells using EF specific 
primers demonstrated the presence of a 700 bp transcript· To further verify that the 
PCR product was EF-specific, nested PCR analysis was carried out using primers 
flanking a 315 bp region· This was further confirmed by subjecting it to sequencing 
(data not shown)· This indicates that the EF protein is synthesized in the peritoneal
exudate cells, most likely in the neutrophils· An ~ 800 bp transcript has been reported
from inflammed synovial tissue and peritoneal exudate cells in bacterial peritonitis 
(Seilhamer et al 1989). 
We conclude here that the exudate cells harbour trace amounts of EF/PLA2 protein· 
Its physiological role as a growth factor modulator at the site of inflammation is not yet 
clear· PLA2 has been shown to be involved in mitogenesis and cell proliferation (Arita 
et al 1991)· Earlier we have shown that EF modulates the action of EGF (Mulherkar 
and Deo 1986)· Its presence in the peritoneal exudate cells could establish a novel 
mode of transport of crucial growth factor modulators in repair following injury/ 
inflammation· 
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